



23 February 2024

Revenue Growth and Profitable Third Quarter

For the third quarter ending 31 Dec 2023, Blis Technologies Limited (Blis) delivered revenue growth of 10% on the same period last year and a positive EBITDA result of \$0.3m (unaudited).

Revenue growth came from a 12% increase in B2B revenue and a stronger than expected result for New Zealand and Amazon.

“Momentum continues to build around the successful execution of the refocused strategic plan. This has involved amongst other activities, working closely with business partners to sell more Blis product profitably into B2C and B2B channels.” said Scott Johnson, CEO.

Based on the latest customer sales forecasts and market feedback, guidance is for full year revenue to be about \$11.0m, with EBITDA in the range of breakeven to \$0.3m. This marks a return to profitability for the company.

Ends

For further information, please contact:

Scott Johnson
CEO
+64 21 488 831

About Blis Technologies Ltd

Delivering proven health benefits through evidence-based, advanced probiotics

Blis Technologies is an NZX-listed manufacturer of advanced probiotic strains that go beyond the gut. Combining innovation with evidence-based research and the highest quality production controls enables the delivery of probiotic solutions for specific health targets including throat health, halitosis (bad breath), immune support, teeth and gum health and skin health. BLIS® products are sold throughout New Zealand and in Asia, Europe and the USA. More information about Blis Technologies Ltd can be found at www.blis.co.nz.